PE20160898A1 - (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbencil)pirrolidin-2-ona y sus profarmacos para el tratamiento de trastornos psiquiatricos - Google Patents
(r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbencil)pirrolidin-2-ona y sus profarmacos para el tratamiento de trastornos psiquiatricosInfo
- Publication number
- PE20160898A1 PE20160898A1 PE2016001105A PE2016001105A PE20160898A1 PE 20160898 A1 PE20160898 A1 PE 20160898A1 PE 2016001105 A PE2016001105 A PE 2016001105A PE 2016001105 A PE2016001105 A PE 2016001105A PE 20160898 A1 PE20160898 A1 PE 20160898A1
- Authority
- PE
- Peru
- Prior art keywords
- methylbenzyl
- fluoro
- piperidin
- hydroxyphenil
- ona
- Prior art date
Links
- -1 4-METHYLBENZYL Chemical class 0.000 title abstract 3
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925405P | 2014-01-09 | 2014-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160898A1 true PE20160898A1 (es) | 2016-09-10 |
Family
ID=52444626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001105A PE20160898A1 (es) | 2014-01-09 | 2015-01-08 | (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbencil)pirrolidin-2-ona y sus profarmacos para el tratamiento de trastornos psiquiatricos |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US9187506B2 (https=) |
| EP (2) | EP3092223B1 (https=) |
| JP (1) | JP6629738B2 (https=) |
| KR (1) | KR102331120B1 (https=) |
| AR (1) | AR102019A1 (https=) |
| AU (1) | AU2015204785A1 (https=) |
| CA (1) | CA2936338A1 (https=) |
| CL (1) | CL2016001744A1 (https=) |
| CY (1) | CY1122768T1 (https=) |
| DK (1) | DK3092223T3 (https=) |
| EA (1) | EA201691133A1 (https=) |
| ES (1) | ES2771825T3 (https=) |
| HR (1) | HRP20200161T1 (https=) |
| HU (1) | HUE048750T2 (https=) |
| IL (1) | IL246596A0 (https=) |
| LT (1) | LT3092223T (https=) |
| MX (1) | MX2016008715A (https=) |
| PE (1) | PE20160898A1 (https=) |
| PL (1) | PL3092223T3 (https=) |
| PT (1) | PT3092223T (https=) |
| RS (1) | RS59858B1 (https=) |
| SG (1) | SG11201605620QA (https=) |
| SI (1) | SI3092223T1 (https=) |
| SM (1) | SMT202000094T1 (https=) |
| TW (1) | TW201612169A (https=) |
| UY (1) | UY35946A (https=) |
| WO (1) | WO2015105929A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| ES2822830T3 (es) | 2015-10-14 | 2021-05-05 | Bristol Myers Squibb Co | Antagonistas selectivos de NR2B |
| JP6938485B2 (ja) * | 2015-10-14 | 2021-09-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 選択的ｎｒ２ｂアンタゴニスト |
| US12086719B2 (en) * | 2019-10-11 | 2024-09-10 | Royal Bank Of Canada | System and method of machine learning using embedding networks |
| WO2024197289A1 (en) * | 2023-03-22 | 2024-09-26 | Gilgamesh Pharmaceuticals, Inc. | Negative allosteric modulators of glun2b receptors and methods of making and using the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| EA200200952A1 (ru) | 2000-04-26 | 2003-02-27 | Уорнер-Ламберт Компани | Производные циклогексиламина в качестве селективных антагонистов подтипов nmda-рецепторов |
| JPWO2003035641A1 (ja) | 2001-10-22 | 2005-02-10 | 塩野義製薬株式会社 | 新規カルバモイルピロリドン誘導体 |
| DE602004015610D1 (de) | 2003-06-04 | 2008-09-18 | Merck & Co Inc | 3-fluoro-piperidine als nmda/nr2b antagonisten |
| MXPA06003748A (es) | 2003-10-08 | 2006-06-14 | Pfizer | Compuestos de lactama condensada. |
| EP2520567A3 (en) * | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| KR20100045983A (ko) | 2007-06-29 | 2010-05-04 | 에모리 유니버시티 | 신경보호를 위한 ｎｍｄａ 수용체 길항물질 |
| EP2231655B1 (en) * | 2007-11-13 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain |
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
-
2015
- 2015-01-07 US US14/591,372 patent/US9187506B2/en active Active
- 2015-01-08 AU AU2015204785A patent/AU2015204785A1/en not_active Abandoned
- 2015-01-08 PE PE2016001105A patent/PE20160898A1/es unknown
- 2015-01-08 WO PCT/US2015/010552 patent/WO2015105929A1/en not_active Ceased
- 2015-01-08 MX MX2016008715A patent/MX2016008715A/es unknown
- 2015-01-08 HR HRP20200161TT patent/HRP20200161T1/hr unknown
- 2015-01-08 EA EA201691133A patent/EA201691133A1/ru unknown
- 2015-01-08 ES ES15702312T patent/ES2771825T3/es active Active
- 2015-01-08 PT PT157023128T patent/PT3092223T/pt unknown
- 2015-01-08 SG SG11201605620QA patent/SG11201605620QA/en unknown
- 2015-01-08 RS RS20200109A patent/RS59858B1/sr unknown
- 2015-01-08 EP EP15702312.8A patent/EP3092223B1/en active Active
- 2015-01-08 LT LTEP15702312.8T patent/LT3092223T/lt unknown
- 2015-01-08 SM SM20200094T patent/SMT202000094T1/it unknown
- 2015-01-08 KR KR1020167021355A patent/KR102331120B1/ko not_active Expired - Fee Related
- 2015-01-08 JP JP2016545818A patent/JP6629738B2/ja not_active Expired - Fee Related
- 2015-01-08 PL PL15702312T patent/PL3092223T3/pl unknown
- 2015-01-08 SI SI201531064T patent/SI3092223T1/sl unknown
- 2015-01-08 EP EP19212924.5A patent/EP3677578A1/en not_active Withdrawn
- 2015-01-08 TW TW104100590A patent/TW201612169A/zh unknown
- 2015-01-08 DK DK15702312.8T patent/DK3092223T3/da active
- 2015-01-08 HU HUE15702312A patent/HUE048750T2/hu unknown
- 2015-01-08 CA CA2936338A patent/CA2936338A1/en not_active Abandoned
- 2015-01-09 AR ARP150100067A patent/AR102019A1/es unknown
- 2015-01-09 UY UY0001035946A patent/UY35946A/es unknown
- 2015-10-13 US US14/881,932 patent/US20160030456A1/en not_active Abandoned
-
2016
- 2016-07-04 IL IL246596A patent/IL246596A0/en unknown
- 2016-07-07 CL CL2016001744A patent/CL2016001744A1/es unknown
- 2016-11-21 US US15/357,102 patent/US20170065573A1/en not_active Abandoned
-
2017
- 2017-04-18 US US15/490,558 patent/US20170216325A1/en not_active Abandoned
- 2017-08-17 US US15/679,847 patent/US20170340653A1/en not_active Abandoned
- 2017-12-19 US US15/846,914 patent/US20180104265A1/en not_active Abandoned
-
2018
- 2018-05-04 US US15/971,049 patent/US20180250316A1/en not_active Abandoned
- 2018-12-19 US US16/225,631 patent/US20190125770A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,843 patent/US20190314392A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,960 patent/US20200297742A1/en not_active Abandoned
- 2020-02-07 CY CY20201100120T patent/CY1122768T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001547A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa. | |
| EA201691853A1 (ru) | Агонисты мускариновых рецепторов | |
| PE20170664A1 (es) | Agonistas del receptor de apelina(apj) y usos de los mismos | |
| EA201890086A1 (ru) | 1,4-замещенные производные пиперидина | |
| MX388682B (es) | Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119. | |
| PE20190395A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| EA202091505A1 (ru) | Триазолазолы циклогексильной кислоты в качестве антагонистов lpa | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| MX2020001236A (es) | Compuestos aza biciclicos como agonistas del receptor muscarinico m1. | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| MX379920B (es) | Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119. | |
| PH12017500821A1 (en) | Morpholine and 1, 4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| EA202090414A1 (ru) | Соединения и их применение | |
| PE20160898A1 (es) | (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbencil)pirrolidin-2-ona y sus profarmacos para el tratamiento de trastornos psiquiatricos | |
| EA201791829A1 (ru) | Амидные соединения в качестве агонистов рецептора 5-ht | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| NO20180002A1 (en) | Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors | |
| EA202191515A1 (ru) | Фармацевтическая композиция, содержащая апиксабан | |
| JOP20190050A1 (ar) | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي | |
| EA201691539A1 (ru) | 2,7-диазаспиро[3.5]нонановые соединения | |
| PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
| PE20170770A1 (es) | Metodos y composiciones para tratar trastornos relacionados con vih |